{"medgen_id":"C3178805","public_definition":"Heterotaxy syndrome is a condition in which the internal organs are abnormally arranged in the chest and abdomen. The term \"heterotaxy\" is from the Greek words \"heteros,\" meaning \"other than,\" and \"taxis,\" meaning \"arrangement.\" Individuals with this condition have complex birth defects affecting the heart, lungs, liver, spleen, intestines, and other organs.In the normal body, most of the organs in the chest and abdomen have a particular location on the right or left side. For example, the heart, spleen, and pancreas are on the left side of the body, and most of the liver is on the right. This normal arrangement of the organs is known as \"situs solitus.\" Rarely, the orientation of the internal organs is completely flipped from right to left, a situation known as \"situs inversus.\" This mirror-image orientation usually does not cause any health problems, unless it occurs as part of a syndrome affecting other parts of the body. Heterotaxy syndrome is an arrangement of internal organs somewhere between situs solitus and situs inversus; this condition is also known as \"situs ambiguus.\" Unlike situs inversus, the abnormal arrangement of organs in heterotaxy syndrome often causes serious health problems.Heterotaxy syndrome can alter the structure of the heart, including the attachment of the large blood vessels that carry blood to and from the rest of the body. It can also affect the structure of the lungs, such as the number of lobes in each lung and the length of the tubes (called bronchi) that lead from the windpipe to the lungs. In the abdomen, the condition can cause a person to have no spleen (asplenia) or multiple small, poorly functioning spleens (polysplenia). The liver may lie across the middle of the body instead of being in its normal position to the right of the stomach. Some affected individuals also have intestinal malrotation, which is an abnormal twisting of the intestines that occurs in the early stages of development before birth.Depending on the organs involved, signs and symptoms of heterotaxy syndrome can include a bluish appearance of the skin or lips (cyanosis, which is due to a shortage of oxygen), breathing difficulties, an increased risk of infections, and problems with digesting food. The most serious complications are generally caused by critical congenital heart disease, a group of complex heart defects that are present from birth. Biliary atresia, a problem with the bile ducts in the liver, can also cause severe health problems in infancy.The severity of heterotaxy syndrome varies depending on the specific abnormalities involved. Some affected individuals have only mild health problems related to the condition. At the other end of the spectrum, heterotaxy syndrome can be life-threatening in infancy or childhood, even with treatment.","alternate_symbols":[],"keywords":[],"attribute_content":[],"id":"16650","alternate_names":["Heterotaxy syndrome"],"type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"MONDO:0018677\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"450\"}","{\"db\":\"NCI\",\"id\":\"C117273\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Heterotaxy syndrome\"}","{\"db\":\"Orphanet\",\"id\":\"450\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"heterotaxy-syndrome\",\"ref_field\":\"public_definition\"}"],"name":"Heterotaxia"}
{"medgen_id":"C0795953","public_definition":"L1 syndrome involves a phenotypic spectrum ranging from severe to mild and includes three clinical phenotypes: X-linked hydrocephalus with stenosis of the aqueduct of Sylvius (HSAS). MASA (mental retardation [intellectual disability], aphasia [delayed speech], spastic paraplegia [shuffling gait], adducted thumbs) syndrome including X-linked complicated hereditary spastic paraplegia type 1. X-linked complicated corpus callosum agenesis. Males with HSAS are born with severe hydrocephalus, adducted thumbs, and spasticity; intellectual disability is severe. In less severely affected males, hydrocephalus may be subclinically present and documented only because of developmental delay; intellectual disability ranges from mild (IQ: 50-70) to moderate (IQ: 30-50). It is important to note that all phenotypes can be observed in affected individuals within the same family.","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"SPG1","id":"2648","gard_id":"6986","alternate_names":["Adducted thumb with mental retardation","Clasped thumb and mental retardation","Crash syndrome","Gareis-Mason syndrome","MASA Syndrome (Mental Retardation, Adducted Thumbs, Shuffling Gait, and Aphasia)","MENTAL RETARDATION, APHASIA, SHUFFLING GAIT, AND ADDUCTED THUMBS","Mental Retardation Aphasia Shuffling Gait Adducted Thumbs (MASA)","SPASTIC PARAPLEGIA 1, X-LINKED","Spastic paraplegia 1","Thumb congenital clasped with mental retardation"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010559\"}","{\"db\":\"OMIM\",\"id\":\"303350\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2466\"}","{\"db\":\"OMIM\",\"id\":\"303350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, APHASIA, SHUFFLING GAIT, AND ADDUCTED THUMBS\"}","{\"db\":\"OMIM\",\"id\":\"303350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPASTIC PARAPLEGIA 1, X-LINKED\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spastic+paraplegia+1/6675\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Spastic paraplegia 1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6986\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010559\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1484\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"303350\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301657\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1484\",\"@Source\":\"BookShelf\"}]}}","name":"MASA syndrome"}
{"medgen_id":"C0014550","alternate_symbols":[],"keywords":[],"attribute_content":[],"id":"40604","alternate_names":[],"type":"Disease","xrefs":[],"name":"myoclonic epilepsy"}
{"medgen_id":"C3276161","public_definition":"Generalized arterial calcification of infancy (GACI) is characterized by infantile onset of widespread arterial calcification and/or narrowing of large and medium-sized vessels resulting in cardiovascular findings (which can include heart failure, respiratory distress, edema, cyanosis, hypertension, and/or cardiomegaly). Additional findings can include typical skin and retinal manifestations of pseudoxanthoma elasticum (PXE), periarticular calcifications, development of rickets after infancy, cervical spine fusion, and hearing loss. While mortality in infancy is high, survival into the third and fourth decades has occurred.","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"GACI2","id":"16820","alternate_names":[],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013768\"}","{\"db\":\"OMIM\",\"id\":\"614473\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"51608\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Generalized+arterial+calcification+of+infancy+2/8456\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK253403\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614473\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25392903\",\"@Source\":\"PubMed\"},{\"$\":\"NBK253403\",\"@Source\":\"BookShelf\"}]}}","name":"Generalized arterial calcification of infancy 2"}
{"medgen_id":"C3495488","alternate_symbols":["RGS"],"keywords":[],"attribute_content":[],"id":"36422","gard_id":"5701","alternate_names":["Axenfeld-Rieger Syndrome"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0019187\"}","{\"db\":\"OMIM\",\"id\":\"PS180500\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"782\"}","{\"db\":\"OMIM\",\"id\":\"180500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"RGS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5701\",\"ref_field\":\"gard_id\"}"],"name":"Axenfeld-rieger anomaly"}
{"medgen_id":"C4551493","alternate_symbols":[],"keywords":[],"attribute_content":[],"id":"35637","gard_id":"10875","alternate_names":["situs oppositus","situs transversus"],"type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001696\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010029\"}","{\"db\":\"Orphanet\",\"id\":\"157769\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001696\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"situs oppositus\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001696\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"situs transversus\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10875\",\"ref_field\":\"gard_id\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001696\",\"ref_field\":\"name\"}"],"name":"Situs inversus totalis"}
{"medgen_id":"C1847024","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"OCA1B","id":"97","alternate_names":["ALBINISM, OCULOCUTANEOUS, TYPE IB","Albinism, yellow mutant type","Yellow albinism"],"type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"606952\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"352731\"}","{\"db\":\"Orphanet\",\"id\":\"352737\"}","{\"db\":\"Orphanet\",\"id\":\"79434\"}","{\"db\":\"OMIM\",\"id\":\"606933.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALBINISM, OCULOCUTANEOUS, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"606933.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALBINISM, OCULOCUTANEOUS, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"606933.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALBINISM, OCULOCUTANEOUS, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"606933.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALBINISM, OCULOCUTANEOUS, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"606933.0024\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALBINISM, OCULOCUTANEOUS, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"606933.0037\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALBINISM, OCULOCUTANEOUS, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"606952\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALBINISM, OCULOCUTANEOUS, TYPE IB\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Oculocutaneous+albinism+type+1B/5316\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606952\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301345\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1166\",\"@Source\":\"BookShelf\"}]}}","name":"Oculocutaneous albinism type 1B"}
{"medgen_id":"C4551985","public_definition":"Generalized arterial calcification of infancy (GACI) is characterized by infantile onset of widespread arterial calcification and/or narrowing of large and medium-sized vessels resulting in cardiovascular findings (which can include heart failure, respiratory distress, edema, cyanosis, hypertension, and/or cardiomegaly). Additional findings can include typical skin and retinal manifestations of pseudoxanthoma elasticum (PXE), periarticular calcifications, development of rickets after infancy, cervical spine fusion, and hearing loss. While mortality in infancy is high, survival into the third and fourth decades has occurred.","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"GACI1","id":"445","alternate_names":["Idiopathic infantile arterial calcification","Occlusive infantile arteriopathy"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008817\"}","{\"db\":\"OMIM\",\"id\":\"208000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"51608\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK253403\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"208000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25392903\",\"@Source\":\"PubMed\"},{\"$\":\"NBK253403\",\"@Source\":\"BookShelf\"}]}}","name":"Arterial calcification, generalized, of infancy, 1"}
{"medgen_id":"C1864880","alternate_symbols":[],"keywords":[],"attribute_content":[],"id":"2030","alternate_names":["HBV, SUSCEPTIBILITY TO"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012488\"}","{\"db\":\"OMIM\",\"id\":\"610424\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"610424\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HBV, SUSCEPTIBILITY TO\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hepatitis+b+virus%2C+susceptibility+to/8510\",\"ref_field\":\"name\"}"],"name":"Hepatitis b virus, susceptibility to"}
{"medgen_id":"C0027672","alternate_symbols":[],"keywords":["Hereditary cancer syndrome","Neoplasm"],"attribute_content":[],"id":"18746","alternate_names":["Cancer predisposition","Hereditary Cancer Syndrome","Neoplastic Syndromes, Hereditary","Tumor predisposition"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0015356\"}","{\"db\":\"Orphanet\",\"id\":\"140162\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+Cancer/3345\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cancer predisposition\"}","{\"db\":\"MeSH\",\"id\":\"D009386\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neoplastic Syndromes, Hereditary\"}","{\"db\":\"SNOMED CT\",\"id\":\"699346009\",\"ref_field\":\"name\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"IARC, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3075918\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}}]}","name":"Hereditary cancer-predisposing syndrome"}
{"medgen_id":"C2981140","public_definition":"Glaucoma is a group of eye disorders in which the optic nerves connecting the eyes and the brain are progressively damaged. This damage can lead to reduction in side (peripheral) vision and eventual blindness. Other signs and symptoms may include bulging eyes, excessive tearing, and abnormal sensitivity to light (photophobia). The term \"early-onset glaucoma\" may be used when the disorder appears before the age of 40.In most people with glaucoma, the damage to the optic nerves is caused by increased pressure within the eyes (intraocular pressure). Intraocular pressure depends on a balance between fluid entering and leaving the eyes.Usually glaucoma develops in older adults, in whom the risk of developing the disorder may be affected by a variety of medical conditions including high blood pressure (hypertension) and diabetes mellitus, as well as family history. The risk of early-onset glaucoma depends mainly on heredity.Structural abnormalities that impede fluid drainage in the eye may be present at birth and usually become apparent during the first year of life. Such abnormalities may be part of a genetic disorder that affects many body systems, called a syndrome. If glaucoma appears before the age of 5 without other associated abnormalities, it is called primary congenital glaucoma.Other individuals experience early onset of primary open-angle glaucoma, the most common adult form of glaucoma. If primary open-angle glaucoma develops during childhood or early adulthood, it is called juvenile open-angle glaucoma.","alternate_symbols":[],"keywords":[],"attribute_content":[],"id":"22162","alternate_names":["Childhood glaucoma","Developmental glaucoma","Infantile glaucoma","Pediatric glaucoma"],"type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001087\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0020367\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001087\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Developmental glaucoma\"}","{\"db\":\"SNOMED CT\",\"id\":\"71111008\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"early-onset-glaucoma\",\"ref_field\":\"public_definition\"}"],"name":"Glaucoma of childhood"}
{"medgen_id":"C1968949","public_definition":"Congenital anomalies of kidney and urinary tract (CAKUT) is a group of abnormalities affecting the kidneys or other structures of the urinary tract. The additional parts of the urinary tract that may be affected include the bladder, the tubes that carry urine from each kidney to the bladder (the ureters), and the tube that carries urine from the bladder out of the body (the urethra). CAKUT results from abnormal development of the urinary system and is present from birth (congenital), although the abnormality may not become apparent until later in life.Individuals with CAKUT have one or more kidney or urinary tract abnormalities. For paired structures, like the kidneys and ureters, one or both may be affected. Many different developmental abnormalities are classified as CAKUT, including underdevelopment or absence of a kidney (renal hypodysplasia or agenesis), a kidney formed of fluid-filled sacs called cysts (multicystic dysplastic kidney), buildup of urine in the kidneys (hydronephrosis), an extra ureter leading to the kidney (duplex kidney or duplicated collecting system), a blockage in a ureter where it joins the kidney (ureteropelvic junction obstruction), an abnormally wide ureter (megaureter), backflow of urine from the bladder into the ureter (vesicoureteral reflux), and an abnormal membrane in the urethra that blocks the flow of urine out of the bladder (posterior urethral valve).CAKUT varies in severity. The abnormalities can result in recurrent urinary tract infections or a buildup of urine in the urinary tract, which may damage the kidneys or other structures. Severe CAKUT can result in life-threatening kidney failure and end-stage renal disease.CAKUT is often one of several features of a condition that affects multiple body systems (syndromic CAKUT). For example, renal coloboma syndrome, 17q12 deletion syndrome, renal cysts and diabetes (RCAD) syndrome, Fraser syndrome, Townes-Brocks syndrome, and branchio-oto-renal syndrome can cause kidney or urinary tract abnormalities in addition to other problems. However, urinary system abnormalities sometimes occur without other signs and symptoms, which is known as nonsyndromic or isolated CAKUT.","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"CAKUT","id":"34805","alternate_names":["Congenital anomalies of the kidney and urinary tract"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0019719\"}","{\"db\":\"OMIM\",\"id\":\"PS610805\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"93545\"}","{\"db\":\"OMIM\",\"id\":\"PS610805\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"congenital-anomalies-of-kidney-and-urinary-tract\",\"ref_field\":\"public_definition\"}"],"name":"Congenital anomalies of kidney and urinary tract"}
{"medgen_id":"C1833296","public_definition":"CHMP2B frontotemporal dementia (CHMP2B-FTD) has been described in a single family from Denmark, in one individual with familial FTD from Belgium, and in one individual with FTD and no family history. It typically starts between ages 46 and 65 years with subtle personality changes and slowly progressive behavioral changes, dysexecutive syndrome, dyscalculia, and language disturbances. Disinhibition or loss of initiative is the most common presenting symptom. The disease progresses over a few years into profound dementia with extrapyramidal symptoms and mutism. Several individuals have developed an asymmetric akinetic rigid syndrome with arm and gait dystonia and pyramidal signs that may be related to treatment with neuroleptic drugs. Symptoms and disease course are highly variable. Disease duration may be as short as three years or longer than 20 years.","alternate_symbols":["ALS17","FTD3"],"keywords":[],"attribute_content":[],"symbol":"FTDALS7","id":"1899","alternate_names":["AMYOTROPHIC LATERAL SCLEROSIS, CHMP2B-RELATED","CHMP2B-Related Frontotemporal Dementia","FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 7"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010936\"}","{\"db\":\"OMIM\",\"id\":\"600795\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"275864\"}","{\"db\":\"Orphanet\",\"id\":\"282\"}","{\"db\":\"OMIM\",\"id\":\"600795\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMYOTROPHIC LATERAL SCLEROSIS, CHMP2B-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"600795\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 7\"}","{\"db\":\"OMIM\",\"id\":\"609512.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 7\"}","{\"db\":\"OMIM\",\"id\":\"609512.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 7\"}","{\"db\":\"OMIM\",\"id\":\"609512.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 7\"}","{\"db\":\"OMIM\",\"id\":\"609512.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 7\"}","{\"db\":\"OMIM\",\"id\":\"609512.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 7\"}","{\"db\":\"OMIM\",\"id\":\"609512.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 7\"}","{\"db\":\"OMIM\",\"id\":\"600795\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ALS17\"}","{\"db\":\"OMIM\",\"id\":\"600795\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FTD3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"CHMP2B-Related+Frontotemporal+Dementia/7968\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1199\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"600795\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301378\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1199\",\"@Source\":\"BookShelf\"}]}}","name":"Frontotemporal Dementia, Chromosome 3-Linked"}
{"medgen_id":"C3549742","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"LBC","id":"17993","alternate_names":["BREAST CANCER, LOBULAR, SOMATIC","Breast lobular carcinoma"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0000552\"}","{\"db\":\"OMIM\",\"id\":\"192090.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BREAST CANCER, LOBULAR, SOMATIC\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0000552\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Breast lobular carcinoma\"}","{\"db\":\"OMIM\",\"id\":\"137215\",\"ref_field\":\"symbol\"}"],"name":"Breast cancer, lobular"}
{"medgen_id":"C0432243","alternate_symbols":["SEMDJL"],"keywords":[],"attribute_content":[],"symbol":"SEMDJL1","id":"43486","gard_id":"4982","alternate_names":["Spondyloepimetaphyseal dysplasia joint laxity"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0019675\"}","{\"db\":\"OMIM\",\"id\":\"PS271640\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"93359\"}","{\"db\":\"OMIM\",\"id\":\"271640\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SEMDJL\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4982\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"PS271640\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"254100000\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529250\",\"ref_field\":\"symbol\"}"],"name":"Spondyloepimetaphyseal dysplasia with joint laxity"}
{"medgen_id":"C0038015","public_definition":"Spondyloepiphyseal dysplasia congenita is an autosomal dominant chondrodysplasia characterized by disproportionate short stature (short trunk), abnormal epiphyses, and flattened vertebral bodies. Skeletal features are manifested at birth and evolve with time. Other features include myopia and/or retinal degeneration with retinal detachment and cleft palate (summary by Anderson et al., 1990).","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"SEDC","id":"4455","gard_id":"4987","alternate_names":["SED congenita","Spondyloepiphyseal dysplasia","Spondyloepiphyseal dysplasia, congenital type"],"type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002655\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002776\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005893\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008471\"}","{\"db\":\"OMIM\",\"id\":\"183900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"94068\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002655\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Spondyloepiphyseal dysplasia\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4987\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spondyloepiphyseal+dysplasia+congenita/6821\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008471\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"183900\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"183900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31021589\",\"@Source\":\"PubMed\"},{\"$\":\"NBK540447\",\"@Source\":\"BookShelf\"}]}}","name":"Spondyloepiphyseal dysplasia congenita"}
{"medgen_id":"C1845055","public_definition":"Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay / intellectual disability (DD/ID). Craniofacial abnormalities include small head circumference, telecanthus or widely spaced eyes, short triangular nose, tented upper lip, and thick or everted lower lip with coarsening of the facial features over time. While all affected individuals have a normal 46,XY karyotype, genital anomalies comprise a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia, to normal-appearing female external genitalia. Alpha-thalassemia, observed in about 75% of affected individuals, is mild and typically does not require treatment. Osteosarcoma has been reported in a few males with germline pathogenic variants.","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"ATRX","id":"281","gard_id":"5864","alternate_names":["ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED","ATR, nondeletion type","ATR-X syndrome","Alpha thalassemia mental retardation syndrome, nondeletion type, X-linked","Alpha-Thalassemia X-Linked Intellectual Disability  Syndrome","Alpha-thalassemia X-linked mental retardation syndrome","XLMR hypotonic face syndrome"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010519\"}","{\"db\":\"OMIM\",\"id\":\"301040\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"847\"}","{\"db\":\"OMIM\",\"id\":\"300032.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300032.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"301040\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED\"}","{\"db\":\"Genetic Alliance\",\"id\":\"ATR-X+Syndrome/647\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ATR-X syndrome\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5864\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010519\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"715342005\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1449\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"301040\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301622\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1449\",\"@Source\":\"BookShelf\"}]}}","name":"Alpha thalassemia-X-linked intellectual disability syndrome"}
{"medgen_id":"C4021133","alternate_symbols":[],"keywords":[],"attribute_content":[],"id":"29561","alternate_names":["Left ventricular non-compaction cardiomyopathy"],"type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011664\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011664\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Left ventricular non-compaction cardiomyopathy\"}"],"name":"Cardiomyopathy, left ventricular noncompaction"}
{"medgen_id":"C0020302","alternate_symbols":[],"keywords":[],"attribute_content":[],"id":"43784","alternate_names":[],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0020366\"}","{\"db\":\"Orphanet\",\"id\":\"98976\"}","{\"db\":\"SNOMED CT\",\"id\":\"204113001\",\"ref_field\":\"name\"}"],"name":"Congenital glaucoma"}
{"medgen_id":"C1839909","public_definition":"L1 syndrome involves a phenotypic spectrum ranging from severe to mild and includes three clinical phenotypes: X-linked hydrocephalus with stenosis of the aqueduct of Sylvius (HSAS). MASA (mental retardation [intellectual disability], aphasia [delayed speech], spastic paraplegia [shuffling gait], adducted thumbs) syndrome including X-linked complicated hereditary spastic paraplegia type 1. X-linked complicated corpus callosum agenesis. Males with HSAS are born with severe hydrocephalus, adducted thumbs, and spasticity; intellectual disability is severe. In less severely affected males, hydrocephalus may be subclinically present and documented only because of developmental delay; intellectual disability ranges from mild (IQ: 50-70) to moderate (IQ: 30-50). It is important to note that all phenotypes can be observed in affected individuals within the same family.","alternate_symbols":[],"keywords":[],"attribute_content":[],"id":"4857","gard_id":"12526","alternate_names":[],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010569\"}","{\"db\":\"OMIM\",\"id\":\"304100\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1497\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12526\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"CORPUS+CALLOSUM%2C+PARTIAL+AGENESIS+OF%2C+X-LINKED/8096\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1484\",\"ref_field\":\"public_definition\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301657\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1484\",\"@Source\":\"BookShelf\"}]}}","name":"Corpus callosum, partial agenesis of, X-linked"}
{"medgen_id":"CN293413","alternate_symbols":["NEDABA"],"keywords":[],"attribute_content":[],"symbol":"BABS","id":"54615","alternate_names":["NEURODEVELOPMENTAL DISORDER WITH ALOPECIA AND BRAIN ABNORMALITIES"],"type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"619075\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"619075\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURODEVELOPMENTAL DISORDER WITH ALOPECIA AND BRAIN ABNORMALITIES\"}","{\"db\":\"OMIM\",\"id\":\"619075\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NEDABA\"}","{\"db\":\"OMIM\",\"id\":\"165640.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"165640.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"165640.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"165640.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"165640.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"619075\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"619075\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"BACHMANN-BUPP SYNDROME"}
{"medgen_id":"C1865270","alternate_symbols":["BSND"],"keywords":[],"attribute_content":[],"symbol":"BARTS4A","id":"4662","alternate_names":["BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS","BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS","Bartter syndrome type 4","Bartter syndrome with sensorineural deafness"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011242\"}","{\"db\":\"OMIM\",\"id\":\"602522\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"112\"}","{\"db\":\"OMIM\",\"id\":\"602522\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS\"}","{\"db\":\"OMIM\",\"id\":\"602522\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bartter+Syndrome+Type+4/749\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Bartter syndrome type 4\"}","{\"db\":\"OMIM\",\"id\":\"602522\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BSND\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011242\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602522\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Bartter disease type 4a"}
{"medgen_id":"C1867773","public_definition":"Hereditary cerebral amyloid angiopathy is a condition that can cause a progressive loss of intellectual function (dementia), stroke, and other neurological problems starting in mid-adulthood. Due to neurological decline, this condition is typically fatal in one's sixties, although there is variation depending on the severity of the signs and symptoms. Most affected individuals die within a decade after signs and symptoms first appear, although some people with the disease have survived longer.There are many different types of hereditary cerebral amyloid angiopathy. The different types are distinguished by their genetic cause and the signs and symptoms that occur. The various types of hereditary cerebral amyloid angiopathy are named after the regions where they were first diagnosed.The Dutch type of hereditary cerebral amyloid angiopathy is the most common form. Stroke is frequently the first sign of the Dutch type and is fatal in about one third of people who have this condition. Survivors often develop dementia and have recurrent strokes. About half of individuals with the Dutch type who have one or more strokes will have recurrent seizures (epilepsy).People with the Flemish and Italian types of hereditary cerebral amyloid angiopathy are prone to recurrent strokes and dementia. Individuals with the Piedmont type may have one or more strokes and typically experience impaired movements, numbness or tingling (paresthesias), confusion, or dementia.The first sign of the Icelandic type of hereditary cerebral amyloid angiopathy is typically a stroke followed by dementia. Strokes associated with the Icelandic type usually occur earlier than the other types, with individuals typically experiencing their first stroke in their twenties or thirties.Strokes are rare in people with the Arctic type of hereditary cerebral amyloid angiopathy, in which the first sign is usually memory loss that then progresses to severe dementia. Strokes are also uncommon in individuals with the Iowa type. This type is characterized by memory loss, problems with vocabulary and the production of speech, personality changes, and involuntary muscle twitches (myoclonus).Two types of hereditary cerebral amyloid angiopathy, known as familial British dementia and familial Danish dementia, are characterized by dementia and movement problems. Strokes are uncommon in these types. People with the Danish type may also have clouding of the lens of the eyes (cataracts) or deafness.","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"FBD","id":"867","gard_id":"8344","alternate_names":["CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 1","Cerebral amyloid angiopathy, British type","Dementia familial British","Presenile dementia with spastic ataxia"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008306\"}","{\"db\":\"OMIM\",\"id\":\"176500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"439254\"}","{\"db\":\"Orphanet\",\"id\":\"97345\"}","{\"db\":\"OMIM\",\"id\":\"176500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Dementia+Familial+British/2182\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Dementia familial British\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8344\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008306\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"hereditary-cerebral-amyloid-angiopathy\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"176500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"ABri amyloidosis"}
{"medgen_id":"C3150692","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"ALS12","id":"6638","alternate_names":["AMYOTROPHIC LATERAL SCLEROSIS 12 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013264\"}","{\"db\":\"OMIM\",\"id\":\"613435\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"803\"}","{\"db\":\"OMIM\",\"id\":\"613435\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMYOTROPHIC LATERAL SCLEROSIS 12 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Amyotrophic+lateral+sclerosis+type+12/7688\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613435\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301623\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1450\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Orphanet, 2007\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Orphanet, Amyotrophic lateral sclerosis, 2007\"},\"URL\":{\"$\":\"https://www.orpha.net/data/patho/Pro/en/Emergency_AmyotrophicLateralSclerosis.pdf\"}}]}","name":"Amyotrophic lateral sclerosis type 12"}
{"medgen_id":"C1691215","alternate_symbols":[],"keywords":[],"attribute_content":[],"id":"21376","alternate_names":[],"type":"Finding","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003244\",\"type\":\"primary\"}","{\"db\":\"SNOMED CT\",\"id\":\"204888000\",\"ref_field\":\"name\"}"],"name":"Hypospadias, penile"}
{"medgen_id":"C0376545","alternate_symbols":[],"keywords":[],"attribute_content":[],"id":"17642","alternate_names":["Blood tumor","Hematologic cancer","Hematological malignancies","Hematological neoplasm"],"type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004377\",\"type\":\"primary\"}","{\"db\":\"MeSH\",\"id\":\"D019337\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004377\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Blood tumor\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004377\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hematological neoplasm\"}","{\"db\":\"SNOMED CT\",\"id\":\"129154003\",\"ref_field\":\"name\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"Nguyen et al., 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"10.1371/currents.RRN1236.\",\"@Source\":\"DOI\"}}}","name":"Hematologic neoplasm"}
{"medgen_id":"C0393615","alternate_symbols":[],"keywords":[],"attribute_content":[],"id":"36567","alternate_names":[],"type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS190300\",\"type\":\"Phenotypic series\"}"],"name":"Hereditary essential tremor"}
{"medgen_id":"C1852406","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"BSTVS","id":"1208","gard_id":"332","alternate_names":["Cutis Gyrata syndrome of Beare and Stevenson"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007412\"}","{\"db\":\"OMIM\",\"id\":\"123790\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1555\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cutis+Gyrata+Syndrome+of+Beare+and+Stevenson/2051\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cutis Gyrata syndrome of Beare and Stevenson\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"332\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genomic Diagnostic Laboratory, Division of Genomic Diagnostics,Children's Hospital of Philadelphia\",\"id\":\"FGFR2-35\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007412\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"123790\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301628\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1455\",\"@Source\":\"BookShelf\"}]}}","name":"Beare-Stevenson cutis gyrata syndrome"}
{"medgen_id":"C1568248","alternate_symbols":["CLRN1-N48K","USH3A"],"keywords":[],"attribute_content":[],"symbol":"USH3","id":"5092","alternate_names":["Usher syndrome type 3"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0016485\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0016485\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Usher syndrome type 3\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553458\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"USH3A\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0016485\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21697857\",\"@Source\":\"PubMed\"}}}","name":"Usher Syndrome, Type III"}
{"medgen_id":"C0268583","public_definition":"Isolated methylmalonic acidemia/aciduria, the topic of this GeneReview, is caused by complete or partial deficiency of the enzyme methylmalonyl-CoA mutase (mut0 enzymatic subtype or mutâ€“ enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. Onset of the manifestations of isolated methylmalonic acidemia/aciduria ranges from the neonatal period to adulthood. All phenotypes are characterized by periods of relative health and intermittent metabolic decompensation, usually associated with intercurrent infections and stress. In the neonatal period the disease can present with lethargy, vomiting, hypotonia, hypothermia, respiratory distress, severe ketoacidosis, hyperammonemia, neutropenia, and thrombocytopenia and can result in death within the first four weeks of life. In the infantile/non-B12-responsive phenotype, infants are normal at birth, but develop lethargy, vomiting, dehydration, failure to thrive, hepatomegaly, hypotonia, and encephalopathy within a few weeks to months of age. An intermediate B12-responsive phenotype can occasionally be observed in neonates, but is usually observed in the first months or years of life; affected children exhibit anorexia, failure to thrive, hypotonia, and developmental delay, and sometimes have protein aversion and/or vomiting and lethargy after protein intake. Atypical and \"benign\"/adult methylmalonic acidemia phenotypes are associated with increased, albeit mild, urinary excretion of methylmalonate. Major secondary complications of methylmalonic acidemia include: intellectual impairment (variable); tubulointerstitial nephritis with progressive renal failure; \"metabolic stroke\" (acute and chronic basal ganglia injury) causing a disabling movement disorder with choreoathetosis, dystonia, and para/quadriparesis; pancreatitis; growth failure; functional immune impairment; and optic nerve atrophy.","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"MMA","id":"6374","gard_id":"7033","alternate_names":["Isolated Methylmalonic Acidemia"],"type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002912\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003123\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008295\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0002012\"}","{\"db\":\"MeSH\",\"id\":\"C537358\"}","{\"db\":\"MeSH\",\"id\":\"C537358\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Isolated Methylmalonic Acidemia\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7033\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Methylmalonic+acidemia/4713\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002912\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"42393006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1231\",\"ref_field\":\"public_definition\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301409\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1231\",\"@Source\":\"BookShelf\"}]}}","name":"Methylmalonic acidemia"}
{"medgen_id":"C2750787","public_definition":"Weill-Marchesani syndrome (WMS) is a connective tissue disorder characterized by abnormalities of the lens of the eye, short stature, brachydactyly, joint stiffness, and cardiovascular defects. The ocular problems, typically recognized in childhood, include microspherophakia (small spherical lens), myopia secondary to the abnormal shape of the lens, ectopia lentis (abnormal position of the lens), and glaucoma, which can lead to blindness. Height of adult males is 142-169 cm; height of adult females is 130-157 cm. Autosomal recessive WMS cannot be distinguished from autosomal dominant WMS by clinical findings alone.","alternate_symbols":["WMSL"],"keywords":[],"attribute_content":[],"symbol":"WMS4","id":"6868","alternate_names":["Weill-Marchesani 4 syndrome, recessive","Weill-Marchesani-like syndrome"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013176\"}","{\"db\":\"OMIM\",\"id\":\"613195\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"363992\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Weill-Marchesani-like+syndrome/9474\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Weill-Marchesani-like syndrome\"}","{\"db\":\"OMIM\",\"id\":\"613195\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"WMSL\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1114\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613195\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301293\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1114\",\"@Source\":\"BookShelf\"}]}}","name":"Weill-Marchesani syndrome 4"}
{"medgen_id":"C1850053","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"HLD3","id":"2475","gard_id":"4266","alternate_names":["Perinatal Sudanophilic leukodystrophy"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009843\"}","{\"db\":\"OMIM\",\"id\":\"260600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"280270\"}","{\"db\":\"Orphanet\",\"id\":\"280293\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4266\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009843\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"260600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Hypomyelinating leukodystrophy 3"}
{"medgen_id":"C0265216","public_definition":"L1 syndrome involves a phenotypic spectrum ranging from severe to mild and includes three clinical phenotypes: X-linked hydrocephalus with stenosis of the aqueduct of Sylvius (HSAS). MASA (mental retardation [intellectual disability], aphasia [delayed speech], spastic paraplegia [shuffling gait], adducted thumbs) syndrome including X-linked complicated hereditary spastic paraplegia type 1. X-linked complicated corpus callosum agenesis. Males with HSAS are born with severe hydrocephalus, adducted thumbs, and spasticity; intellectual disability is severe. In less severely affected males, hydrocephalus may be subclinically present and documented only because of developmental delay; intellectual disability ranges from mild (IQ: 50-70) to moderate (IQ: 30-50). It is important to note that all phenotypes can be observed in affected individuals within the same family.","alternate_symbols":["HSAS1","HYCX","XLAS"],"keywords":[],"attribute_content":[],"symbol":"HSAS","id":"6371","gard_id":"434","alternate_names":["Aqueductal stenosis, X-linked","X-Linked Hydrocephalus with Stenosis of the Aqueduct of Sylvius","X-linked hydrocephalus"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010611\"}","{\"db\":\"OMIM\",\"id\":\"307000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2182\"}","{\"db\":\"OMIM\",\"id\":\"307000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HSAS1\"}","{\"db\":\"OMIM\",\"id\":\"307000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HYCX\"}","{\"db\":\"OMIM\",\"id\":\"307000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XLAS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"434\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"X-linked+hydrocephalus+syndrome/9488\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"71779008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1484\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"307000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301657\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1484\",\"@Source\":\"BookShelf\"}]}}","name":"X-linked hydrocephalus syndrome"}
{"medgen_id":"C0220685","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"ACG2","id":"65","gard_id":"8713","alternate_names":["Achondrogenesis, Langer-Saldino type","Chondrogenesis imperfecta"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008702\"}","{\"db\":\"OMIM\",\"id\":\"200610\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"932\"}","{\"db\":\"Orphanet\",\"id\":\"93296\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8713\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008702\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"200610\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31021589\",\"@Source\":\"PubMed\"},{\"$\":\"NBK540447\",\"@Source\":\"BookShelf\"}]}}","name":"Achondrogenesis type II"}
{"medgen_id":"C0268495","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"OCA2","id":"198","gard_id":"4038","alternate_names":["ALBINISM II","Albinism 2","Albinism, oculocutaneous, type II","Albinoidism"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008746\"}","{\"db\":\"OMIM\",\"id\":\"203200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"79432\"}","{\"db\":\"OMIM\",\"id\":\"203200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALBINISM II\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4038\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Oculocutaneous+albinism+type+2/5317\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"26336006\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"203200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301410\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1232\",\"@Source\":\"BookShelf\"}]}}","name":"Tyrosinase-positive oculocutaneous albinism"}
{"medgen_id":"C0410529","public_definition":"Hypochondroplasia is a skeletal dysplasia characterized by short stature; stocky build; disproportionately short arms and legs; broad, short hands and feet; mild joint laxity; and macrocephaly. Radiologic features include shortening of long bones with mild metaphyseal flare; narrowing of the inferior lumbar interpedicular distances; short, broad femoral neck; and squared, shortened ilia. The skeletal features are very similar to those seen in achondroplasia but tend to be milder. Medical complications common to achondroplasia (e.g., spinal stenosis, tibial bowing, obstructive apnea) occur less frequently in hypochondroplasia but intellectual disability and epilepsy may be more prevalent. Children usually present as toddlers or at early school age with decreased growth velocity leading to short stature and limb disproportion. Other features also become more prominent over time.","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"HCH","id":"5300","gard_id":"6724","alternate_names":[],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007793\"}","{\"db\":\"OMIM\",\"id\":\"146000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"429\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500679\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562498\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6724\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneTests\",\"id\":\"2814\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypochondroplasia/3635\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"205468002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1477\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"146000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301650\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1477\",\"@Source\":\"BookShelf\"}]}}","name":"Hypochondroplasia","disease_mechanism":"gain of function","disease_mechanism_id":"274"}
{"medgen_id":"C0001080","public_definition":"Achondroplasia is the most common cause of disproportionate short stature. Affected individuals have rhizomelic shortening of the limbs, macrocephaly, and characteristic facial features with frontal bossing and midface retrusion. In infancy, hypotonia is typical, and acquisition of developmental motor milestones is often both aberrant in pattern and delayed. Intelligence and life span are usually near normal, although craniocervical junction compression increases the risk of death in infancy. Additional complications include obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis.","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"ACH","id":"66","gard_id":"8173","alternate_names":["Achondroplastic dwarfism"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007037\"}","{\"db\":\"OMIM\",\"id\":\"100800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"15\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000017792\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000193973\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000325183\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332463\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501373\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508854\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508972\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000510685\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514902\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518899\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000523319\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529586\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552209\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556521\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562498\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8173\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneTests\",\"id\":\"2789\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Achondroplasia/113\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"86268005\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1152\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"100800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301331\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1152\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111019\",\"@Source\":\"pmc\"}}]}","name":"Achondroplasia","disease_mechanism":"gain of function","disease_mechanism_id":"274"}
{"medgen_id":"C1868678","public_definition":"Thanatophoric dysplasia (TD) is a short-limb skeletal dysplasia that is usually lethal in the perinatal period. TD is divided into subtypes: TD type I is characterized by micromelia with bowed femurs and, uncommonly, the presence of craniosynostosis of varying severity. TD type II is characterized by micromelia with straight femurs and uniform presence of moderate-to-severe craniosynostosis with cloverleaf skull deformity. Other features common to type I and type II include: short ribs, narrow thorax, relative macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs. Most affected infants die of respiratory insufficiency shortly after birth. Rare long-term survivors have been reported.","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"TD1","id":"4254","alternate_names":["LETHAL SHORT-LIMBED PLATYSPONDYLIC DWARFISM, SAN DIEGO TYPE","PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, SAN DIEGO TYPE"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008546\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1860\"}","{\"db\":\"Orphanet\",\"id\":\"2655\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LETHAL SHORT-LIMBED PLATYSPONDYLIC DWARFISM, SAN DIEGO TYPE\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, SAN DIEGO TYPE\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226129\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327813\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508854\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508990\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514902\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518899\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530324\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562498\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568358\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thanatophoric+dysplasia+type+1/7051\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008546\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1366\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301540\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1366\",\"@Source\":\"BookShelf\"}]}}","name":"Thanatophoric dysplasia type 1","disease_mechanism":"gain of function","disease_mechanism_id":"274"}
{"medgen_id":"C3281201","public_definition":"Coffin-Siris syndrome (CSS) is classically characterized by aplasia or hypoplasia of the distal phalanx or nail of the fifth and additional digits, developmental or cognitive delay of varying degree, distinctive facial features, hypotonia, hirsutism/hypertrichosis, and sparse scalp hair. Congenital anomalies can include malformations of the cardiac, gastrointestinal, genitourinary, and/or central nervous systems. Other findings commonly include feeding difficulties, slow growth, ophthalmologic abnormalities, and hearing impairment.","alternate_symbols":["MRD12"],"keywords":["Neoplasm"],"attribute_content":[],"symbol":"CSS1","id":"824","alternate_names":["Hypertrichosis, hyperkeratosis, mental retardation, and distinctive facial features","Mental retardation, autosomal dominant 12"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007617\"}","{\"db\":\"OMIM\",\"id\":\"135900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1465\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypertrichosis%2C+hyperkeratosis%2C+mental+retardation%2C+and+distinctive+facial+features/3617\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypertrichosis, hyperkeratosis, mental retardation, and distinctive facial features\"}","{\"db\":\"Genetic Alliance\",\"id\":\"MENTAL+RETARDATION%2C+AUTOSOMAL+DOMINANT+12/8820\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mental retardation, autosomal dominant 12\"}","{\"db\":\"OMIM\",\"id\":\"135900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MRD12\"}","{\"db\":\"OMIM\",\"id\":\"614562\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MRD12\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000309827\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501263\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506306\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508459\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508460\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000510938\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527930\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553482\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561944\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK131811\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"135900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23556151\",\"@Source\":\"PubMed\"},{\"$\":\"NBK131811\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31132234\",\"@Source\":\"PubMed\"},{\"$\":\"NBK541502\",\"@Source\":\"BookShelf\"}]}]}","name":"Coffin-Siris syndrome 1","disease_mechanism":"gain of function","disease_mechanism_id":"274"}
{"medgen_id":"C1300257","public_definition":"Thanatophoric dysplasia (TD) is a short-limb skeletal dysplasia that is usually lethal in the perinatal period. TD is divided into subtypes: TD type I is characterized by micromelia with bowed femurs and, uncommonly, the presence of craniosynostosis of varying severity. TD type II is characterized by micromelia with straight femurs and uniform presence of moderate-to-severe craniosynostosis with cloverleaf skull deformity. Other features common to type I and type II include: short ribs, narrow thorax, relative macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs. Most affected infants die of respiratory insufficiency shortly after birth. Rare long-term survivors have been reported.","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"TD2","id":"4255","gard_id":"1402","alternate_names":["Cloverleaf skull with thanatophoric dwarfism","THANATOPHORIC DYSPLASIA WITH STRAIGHT FEMURS AND CLOVERLEAF SKULL","Thanatophoric dysplasia with Kleeblattschaedel"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008547\"}","{\"db\":\"OMIM\",\"id\":\"187601\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2655\"}","{\"db\":\"Orphanet\",\"id\":\"93274\"}","{\"db\":\"OMIM\",\"id\":\"187601\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THANATOPHORIC DYSPLASIA WITH STRAIGHT FEMURS AND CLOVERLEAF SKULL\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226129\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505530\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508854\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508990\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530324\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562498\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568358\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1402\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thanatophoric+dysplasia+type+2/7052\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"389158007\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1366\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"187601\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301540\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1366\",\"@Source\":\"BookShelf\"}]}}","name":"Thanatophoric dysplasia, type 2","disease_mechanism":"gain of function","disease_mechanism_id":"274"}
{"medgen_id":"C3160733","alternate_symbols":["F2"],"keywords":[],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000323271\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000525921\"}]}"],"symbol":"THPH1","id":"24727","gard_id":"10815","alternate_names":["Prothrombin-Related Thrombophilia (Factor II)","THROMBOPHILIA DUE TO FACTOR 2 DEFECT","Thrombosis susceptibility"],"type":"Finding","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008559\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THROMBOPHILIA DUE TO FACTOR 2 DEFECT\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500305\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"F2\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000025288\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000174333\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000321099\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331922\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331933\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332126\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502122\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502510\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503192\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507481\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509249\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511144\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520021\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520078\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521336\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521660\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530629\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000531243\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552060\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556387\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10815\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008559\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301327\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1148\",\"@Source\":\"BookShelf\"}]}}","name":"Thrombophilia due to thrombin defect","disease_mechanism":"gain of function","disease_mechanism_id":"274"}
{"medgen_id":"C4048306","public_definition":"Multiple endocrine neoplasia type 2 (MEN 2) includes the following phenotypes: MEN 2A, FMTC (familial medullary thyroid carcinoma, which may be a variant of MEN 2A), and MEN 2B. All three phenotypes involve high risk for development of medullary carcinoma of the thyroid (MTC); MEN 2A and MEN 2B involve an increased risk for pheochromocytoma; MEN 2A involves an increased risk for parathyroid adenoma or hyperplasia. Additional features in MEN 2B include mucosal neuromas of the lips and tongue, distinctive facies with enlarged lips, ganglioneuromatosis of the gastrointestinal tract, and a marfanoid habitus. MTC typically occurs in early childhood in MEN 2B, early adulthood in MEN 2A, and middle age in FMTC.","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"MEN2","id":"14899","gard_id":"3830","alternate_names":[],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0019003\"}","{\"db\":\"Orphanet\",\"id\":\"653\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000021494\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260603\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000325033\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501433\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501488\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508573\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509879\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520186\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521505\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522280\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522559\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528040\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528367\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528651\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528909\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528911\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528912\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552183\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552245\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553206\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553528\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592320\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3830\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Multiple+endocrine+neoplasia%2C+type+2/4957\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"61808009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1257\",\"ref_field\":\"public_definition\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301434\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1257\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Brandi et al., 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"11739416\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15604628\",\"@Source\":\"PubMed\"}}]}","name":"Multiple endocrine neoplasia, type 2","disease_mechanism":"gain of function","disease_mechanism_id":"274"}
{"medgen_id":"C4551504","alternate_symbols":["ATN"],"keywords":[],"attribute_content":[],"symbol":"OCA1A","id":"96","alternate_names":["Albinism, oculocutaneous, type IA","Oculocutaneous albinism type 1A"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008745\"}","{\"db\":\"OMIM\",\"id\":\"203100\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"352731\"}","{\"db\":\"Orphanet\",\"id\":\"79431\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Oculocutaneous+Albinism+Type+1A/9639\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Oculocutaneous albinism type 1A\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008745\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Oculocutaneous albinism type 1A\"}","{\"db\":\"OMIM\",\"id\":\"203100\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ATN\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520184\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"SNOMED CT\",\"id\":\"6483008\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"203100\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301345\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1166\",\"@Source\":\"BookShelf\"}]}}","name":"Tyrosinase-negative oculocutaneous albinism","disease_mechanism":"loss of function","disease_mechanism_id":"273"}
{"medgen_id":"C1838612","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"RCDP3","id":"3625","gard_id":"9682","alternate_names":["ALKYLGLYCERONE-PHOSPHATE SYNTHASE DEFICIENCY","Alkyglycerone-Phosphate synthase deficiency","Alkyldihydroxyacetonephosphate synthase deficiency"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010823\"}","{\"db\":\"OMIM\",\"id\":\"600121\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"177\"}","{\"db\":\"Orphanet\",\"id\":\"309803\"}","{\"db\":\"OMIM\",\"id\":\"600121\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALKYLGLYCERONE-PHOSPHATE SYNTHASE DEFICIENCY\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000030344\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000070509\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000318886\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508587\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511899\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512398\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518899\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9682\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"600121\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Rhizomelic chondrodysplasia punctata type 3","disease_mechanism":"loss of function","disease_mechanism_id":"273"}
{"medgen_id":"C3280371","public_definition":"Mitochondrial membrane protein-associated neurodegeneration (MPAN) is characterized initially by gait changes followed by progressive spastic paresis, progressive dystonia (which may be limited to the hands and feet or more generalized), neuropsychiatric abnormalities (e.g., emotional lability, depression, anxiety, impulsivity, compulsions, hallucinations, perseveration, inattention, and hyperactivity), and cognitive decline. Additional early findings can include dysphagia, dysarthria, optic atrophy, axonal neuropathy, parkinsonism, and bowel/bladder incontinence. Survival is usually well into adulthood. End-stage disease is characterized by severe dementia, spasticity, dystonia, and parkinsonism.","alternate_symbols":["MPAN"],"keywords":[],"attribute_content":[],"symbol":"NBIA4","id":"16586","gard_id":"12569","alternate_names":["MITOCHONDRIAL PROTEIN-ASSOCIATED NEURODEGENERATION"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013674\"}","{\"db\":\"OMIM\",\"id\":\"614298\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"289560\"}","{\"db\":\"OMIM\",\"id\":\"614298\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL PROTEIN-ASSOCIATED NEURODEGENERATION\"}","{\"db\":\"OMIM\",\"id\":\"614298\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MPAN\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508834\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512825\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520058\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529414\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552041\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553865\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12569\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK185329\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614298\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23447832\",\"@Source\":\"PubMed\"},{\"$\":\"NBK121988\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24575447\",\"@Source\":\"PubMed\"},{\"$\":\"NBK185329\",\"@Source\":\"BookShelf\"}]}]}","name":"Neurodegeneration with brain iron accumulation 4","disease_mechanism":"loss of function","disease_mechanism_id":"273"}
{"medgen_id":"C1845118","alternate_symbols":["SS"],"keywords":[],"attribute_content":[],"symbol":"ISS","id":"4142","alternate_names":[],"type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"300582\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"314795\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508920\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511912\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529040\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"SHORT+STATURE%2C+IDIOPATHIC%2C+X-LINKED/9296\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300582\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Short stature, idiopathic, X-linked","disease_mechanism":"loss of function","disease_mechanism_id":"273"}
{"medgen_id":"C0019202","public_definition":"Wilson disease is a disorder of copper metabolism that can present with hepatic, neurologic, or psychiatric disturbances, or a combination of these, in individuals ranging from age three years to older than 50 years; symptoms vary among and within families. Liver disease includes recurrent jaundice, simple acute self-limited hepatitis-like illness, autoimmune-type hepatitis, fulminant hepatic failure, or chronic liver disease. Neurologic presentations include movement disorders (tremors, poor coordination, loss of fine-motor control, chorea, choreoathetosis) or rigid dystonia (mask-like facies, rigidity, gait disturbance, pseudobulbar involvement). Psychiatric disturbance includes depression, neurotic behaviors, disorganization of personality, and, occasionally, intellectual deterioration. Kayser-Fleischer rings, frequently present, result from copper deposition in Descemet's membrane of the cornea and reflect a high degree of copper storage in the body.","alternate_symbols":["WD"],"keywords":[],"attribute_content":[],"symbol":"WND","id":"6125","gard_id":"7893","alternate_names":["Hepatolenticular degeneration","Wilson's disease"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010200\"}","{\"db\":\"OMIM\",\"id\":\"277900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"905\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Wilson+disease/7506\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Wilson's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"88518009\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Wilson's disease\"}","{\"db\":\"OMIM\",\"id\":\"277900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"WD\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260623\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501125\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503091\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507952\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508735\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509712\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515523\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520058\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521900\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528632\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528928\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529414\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530035\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530097\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552345\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553937\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000567667\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7893\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"wilson-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1512\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"277900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301685\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1512\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"AASLD, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"18506894\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EFNS, 2011\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"20482602\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","name":"Wilson disease","disease_mechanism":"loss of function","disease_mechanism_id":"273"}
{"medgen_id":"C0162635","public_definition":"Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs, and a unique behavior with an inappropriate happy demeanor that includes frequent laughing, smiling, and excitability. Microcephaly and seizures are also common. Developmental delays are first noted at around age six months; however, the unique clinical features of AS do not become manifest until after age one year, and it can take several years before the correct clinical diagnosis is obvious.","alternate_symbols":[],"keywords":[],"attribute_content":["{\"Attribute\":{\"$\":\"imprinting disorder\",\"@Type\":\"mode of inheritance\"},\"XRef\":{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260593\"}}"],"symbol":"AS","id":"404","gard_id":"5810","alternate_names":["HAPPY PUPPET SYNDROME","Happy puppet syndrome (formerly)"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007113\"}","{\"db\":\"OMIM\",\"id\":\"105830\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"72\"}","{\"db\":\"OMIM\",\"id\":\"105830\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HAPPY PUPPET SYNDROME\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226643\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260593\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331374\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503131\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507771\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508896\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508937\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509438\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519582\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520979\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520995\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520996\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520998\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521642\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522320\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525860\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525867\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527540\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529013\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530102\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000531722\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551668\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552178\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552326\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552341\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556577\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556612\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558215\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558216\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558805\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558906\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568029\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568371\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5810\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501320\",\"ref_field\":\"mode_of_inheritance\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Angelman+Syndrome/452\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"angelman-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"76880004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1144\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"105830\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301323\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1144\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111049\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"Eurogentest, 2008\",\"@Type\":\"Translational/Evidence-based\",\"URL\":{\"$\":\"http://www.eurogentest.org/web/files/public/unit3/ClinicalUtilityGeneCards/Indication%20criteria%20-%20AS.pdf\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23519317\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESHG/ASHG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25782669\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"27467454\",\"@Source\":\"PubMed\"}}]}","mode_of_inheritance":"AS is caused by disruption of maternally imprinted UBE3A located within the 15q11.2-q13 Angelman syndrome/Prader-Willi syndrome (AS/PWS) region.","name":"Angelman syndrome","disease_mechanism":"loss of function","disease_mechanism_id":"273"}
{"medgen_id":"C4551478","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"NLS1","id":"3448","alternate_names":[],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009736\"}","{\"db\":\"OMIM\",\"id\":\"256520\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2671\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527475\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"OMIM\",\"id\":\"256520\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Neu-Laxova syndrome 1","disease_mechanism":"loss of function","disease_mechanism_id":"273"}
{"medgen_id":"C0175778","public_definition":"The FLNB disorders include a spectrum of phenotypes ranging from mild to severe. At the mild end are spondylocarpotarsal synostosis (SCT) syndrome and Larsen syndrome; at the severe end are the phenotypic continuum of atelosteogenesis types I (AOI) and III (AOIII) and Piepkorn osteochondrodysplasia (POCD). SCT syndrome is characterized by postnatal disproportionate short stature, scoliosis and lordosis, clubfeet, hearing loss, dental enamel hypoplasia, carpal and tarsal synostosis, and vertebral fusions. Larsen syndrome is characterized by congenital dislocations of the hip, knee, and elbow; clubfeet (equinovarus or equinovalgus foot deformities); scoliosis and cervical kyphosis, which can be associated with a cervical myelopathy; short, broad, spatulate distal phalanges; distinctive craniofacies (prominent forehead, depressed nasal bridge, malar flattening, and widely spaced eyes); vertebral anomalies; and supernumerary carpal and tarsal bone ossification centers. Individuals with SCT syndrome and Larsen syndrome can have midline cleft palate and hearing loss. AOI and AOIII are characterized by severe short-limbed dwarfism; dislocated hips, knees, and elbows; and clubfeet. AOI is lethal in the perinatal period. In individuals with AOIII, survival beyond the neonatal period is possible with intensive and invasive respiratory support. Piepkorn osteochondrodysplasia (POCD) is a perinatal-lethal micromelic dwarfism characterized by flipper-like limbs (polysyndactyly with complete syndactyly of all fingers and toes, hypoplastic or absent first digits, and duplicated intermediate and distal phalanges), macrobrachycephaly, prominant forehead, hypertelorism, and exophthalmos. Occasional features include cleft palate, omphalocele, and cardiac and genitourinary anomalies. The radiographic features at mid-gestation are characteristic.","alternate_symbols":["LRS1"],"keywords":[],"attribute_content":[],"symbol":"LRS","id":"14587","alternate_names":["Bilateral dislocation of the knees, pes cavus, cylindrically shaped fingers and characteristic facies","Larsen syndrome, dominant type"],"type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"150250\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"503\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Larsen+syndrome%2C+dominant+type/4094\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Larsen syndrome, dominant type\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508858\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Larsen+syndrome/4093\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"larsen-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"63387002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK2534\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"150250\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301736\",\"@Source\":\"PubMed\"},{\"$\":\"NBK2534\",\"@Source\":\"BookShelf\"}]}}","name":"Larsen syndrome","disease_mechanism":"loss of function","disease_mechanism_id":"273"}
{"medgen_id":"C1832200","public_definition":"Zellweger spectrum disorder (ZSD) is a phenotypic continuum ranging from severe to mild. While individual phenotypes (e.g., Zellweger syndrome [ZS], neonatal adrenoleukodystrophy [NALD], and infantile Refsum disease [IRD]) were described in the past before the biochemical and molecular bases of this spectrum were fully determined, the term \"ZSD\" is now used to refer to all individuals with a defect in one of the ZSD-PEX genes regardless of phenotype. Individuals with ZSD usually come to clinical attention in the newborn period or later in childhood. Affected newborns are hypotonic and feed poorly. They have distinctive facies, congenital malformations (neuronal migration defects associated with neonatal-onset seizures, renal cysts, and bony stippling [chondrodysplasia punctata] of the patella[e] and the long bones), and liver disease that can be severe. Infants with severe ZSD are significantly impaired and typically die during the first year of life, usually having made no developmental progress. Individuals with intermediate/milder ZSD do not have congenital malformations, but rather progressive peroxisome dysfunction variably manifest as sensory loss (secondary to retinal dystrophy and sensorineural hearing loss), neurologic involvement (ataxia, polyneuropathy, and leukodystrophy), liver dysfunction, adrenal insufficiency, and renal oxalate stones. While hypotonia and developmental delays are typical, intellect can be normal. Some have osteopenia; almost all have ameleogenesis imperfecta in the secondary teeth.","alternate_symbols":["PBDS","ZS"],"keywords":[],"attribute_content":[],"symbol":"PBD, ZSS","id":"5752","alternate_names":["ADRENOLEUKODYSTROPHY, AUTOSOMAL NEONATAL","INFANTILE PHYTANIC ACID STORAGE DISEASE","PEROXISOME BIOGENESIS DISORDER (NALD/IRD)","PEROXISOME BIOGENESIS DISORDER (NEONATAL ADRENOLEUKODYSTROPHY/INFANTILE REFSUM DISEASE)","Zellweger spectrum disorders","Zellweger syndrome spectrum"],"type":"Disease","xrefs":["{\"db\":\"Orphanet\",\"id\":\"79189\"}","{\"db\":\"OMIM\",\"id\":\"601539\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENOLEUKODYSTROPHY, AUTOSOMAL NEONATAL\"}","{\"db\":\"OMIM\",\"id\":\"601539\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INFANTILE PHYTANIC ACID STORAGE DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"601539\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PEROXISOME BIOGENESIS DISORDER (NALD/IRD)\"}","{\"db\":\"OMIM\",\"id\":\"601539\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PEROXISOME BIOGENESIS DISORDER (NEONATAL ADRENOLEUKODYSTROPHY/INFANTILE REFSUM DISEASE)\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500811\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PBDS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500811\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ZS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000004880\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000028499\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000028503\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000070507\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000070509\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000318883\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000318886\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000318975\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500811\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501466\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501472\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501473\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501474\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501625\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501626\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501628\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501629\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501630\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501631\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501632\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501633\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501634\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501635\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501644\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501647\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525961\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Peroxisome+biogenesis+disorders/5684\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1448\",\"ref_field\":\"public_definition\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1448\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301621\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1448\",\"@Source\":\"BookShelf\"}]}}","name":"Peroxisome biogenesis disorders, Zellweger syndrome spectrum","disease_mechanism":"loss of function","disease_mechanism_id":"273"}
{"medgen_id":"C0023931","public_definition":"COL1A1/2 osteogenesis imperfecta (COL1A1/2-OI) is characterized by fractures with minimal or absent trauma, variable dentinogenesis imperfecta (DI), and, in adult years, hearing loss. The clinical features of COL1A1/2-OI represent a continuum ranging from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, normal dentition, normal stature, and normal life span. Fractures can occur in any bone but are most common in the extremities. DI is characterized by gray or brown teeth that may appear translucent, wear down, and break easily. COL1A1/2-OI has been classified into four types based on clinical presentation and radiographic findings. This classification system can be helpful in providing information about prognosis and management for a given individual. The four more common OI types are now referred to as follows: Classic non-deforming OI with blue sclerae (previously OI type I). Perinatally lethal OI (previously OI type II). Progressively deforming OI (previously OI type III). Common variable OI with normal sclerae (previously OI type IV).","alternate_symbols":[],"keywords":[],"attribute_content":[],"symbol":"OI1","id":"5697","gard_id":"8694","alternate_names":["Lobstein disease","Lobstein's Disease","OI TYPE IA","OI type 1","OI type 1A","OI, TYPE I","Osteogenesis imperfecta tarda","Osteogenesis imperfecta type 1","Osteogenesis imperfecta type 1 with dentinogenesis imperfecta","Osteogenesis imperfecta type 1A","Osteogenesis imperfecta with blue sclerae","Osteogenesis imperfecta with opalescent teeth"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008146\"}","{\"db\":\"OMIM\",\"id\":\"166200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"216796\"}","{\"db\":\"Orphanet\",\"id\":\"666\"}","{\"db\":\"OMIM\",\"id\":\"166240\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OI TYPE IA\"}","{\"db\":\"OMIM\",\"id\":\"166200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OI, TYPE I\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008146\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Osteogenesis imperfecta type 1\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260571\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332445\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511197\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521190\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525779\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561718\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562498\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8694\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Osteogenesis+imperfecta+type+1/5454\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"385482004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1295\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"166200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301472\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1295\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EMQN, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3234509\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"Orphanet, 2008\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Orphanet Emergency Guidelines: Osteogenesis imperfecta (OI)\"},\"URL\":{\"$\":\"https://www.orpha.net/data/patho/Pro/en/Emergency_OsteogenesisImperfecta.pdf\"}}]}","name":"Osteogenesis imperfecta type I","disease_mechanism":"loss of function","disease_mechanism_id":"273"}
{"medgen_id":"C3552553","public_definition":"Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is characterized by inappropriately low serum concentrations of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) in the presence of low circulating concentrations of sex steroids. IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%. IGD can first become apparent in infancy, adolescence, or adulthood. Infant boys with congenital IGD often have micropenis and cryptorchidism. Adolescents and adults with IGD have clinical evidence of hypogonadism and incomplete sexual maturation on physical examination. Adult males with IGD tend to have prepubertal testicular volume (i.e., \u003c4 mL), absence of secondary sexual features (e.g., facial and axillary hair growth, deepening of the voice), decreased muscle mass, diminished libido, erectile dysfunction, and infertility. Adult females have little or no breast development and primary amenorrhea. Although skeletal maturation is delayed, the rate of linear growth is usually normal except for the absence of a distinct pubertal growth spurt.","alternate_symbols":["HH5"],"keywords":[],"attribute_content":[],"symbol":"KAL5","id":"5355","gard_id":"10773","alternate_names":["CHD7-Related Isolated Gonadotropin-Releasing Hormone (GnRH) Deficiency","HYPOGONADOTROPHIC HYPOGONADISM 5 WITHOUT ANOSMIA","HYPOGONADOTROPIC HYPOGONADISM 5 WITH ANOSMIA","Kallmann syndrome 5"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012880\"}","{\"db\":\"OMIM\",\"id\":\"612370\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"478\"}","{\"db\":\"OMIM\",\"id\":\"608892.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOGONADOTROPHIC HYPOGONADISM 5 WITHOUT ANOSMIA\"}","{\"db\":\"OMIM\",\"id\":\"608892.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOGONADOTROPIC HYPOGONADISM 5 WITH ANOSMIA\"}","{\"db\":\"OMIM\",\"id\":\"608892.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOGONADOTROPIC HYPOGONADISM 5 WITH ANOSMIA\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Kallmann+syndrome+5/8704\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Kallmann syndrome 5\"}","{\"db\":\"OMIM\",\"id\":\"612370\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HH5\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000334133\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506067\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527475\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556729\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556733\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558347\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10773\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012880\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1334\",\"ref_field\":\"public_definition\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301296\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1117\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301509\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1334\",\"@Source\":\"BookShelf\"}]}]}","name":"Hypogonadotropic hypogonadism 5 with or without anosmia","disease_mechanism":"loss of function","disease_mechanism_id":"273"}
{"medgen_id":"C1859133","public_definition":"Rhizomelic chondrodysplasia punctata type 1 (RCDP1), a peroxisome biogenesis disorder (PBD) has a classic (severe) form and a nonclassic (mild) form. Classic (severe) RCDP1 is characterized by proximal shortening of the humerus (rhizomelia) and to a lesser degree the femur, punctate calcifications in cartilage with epiphyseal and metaphyseal abnormalities (chondrodysplasia punctata, or CDP), coronal clefts of the vertebral bodies, and cataracts that are usually present at birth or appear in the first few months of life. Birth weight, length, and head circumference are often at the lower range of normal; postnatal growth deficiency is profound. Intellectual disability is severe, and the majority of children develop seizures. Most affected children do not survive the first decade of life; a proportion die in the neonatal period. Nonclassic (mild) RCDP1 is characterized by congenital or childhood cataracts, CDP or infrequently, chondrodysplasia manifesting only as mild epiphyseal changes, variable rhizomelia, and milder intellectual disability and growth restriction than classic RCDP1.","alternate_symbols":["CDPR","PBD9"],"keywords":[],"attribute_content":[],"symbol":"RCDP1","id":"5877","gard_id":"6049","alternate_names":["Chondrodysplasia punctata rhizomelic form","Chondrodystrophia calcificans punctata","PEROXISOME BIOGENESIS DISORDER 9"],"type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008972\"}","{\"db\":\"OMIM\",\"id\":\"215100\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"177\"}","{\"db\":\"Orphanet\",\"id\":\"309789\"}","{\"db\":\"OMIM\",\"id\":\"215100\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PEROXISOME BIOGENESIS DISORDER 9\"}","{\"db\":\"OMIM\",\"id\":\"215100\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CDPR\"}","{\"db\":\"OMIM\",\"id\":\"215100\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PBD9\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000004880\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000030344\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000070509\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000318975\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508587\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518899\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529356\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569521\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6049\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Rhizomelic+chondrodysplasia+punctata+type+1/6309\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1270\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"215100\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301447\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1270\",\"@Source\":\"BookShelf\"}]}}","name":"Rhizomelic chondrodysplasia punctata type 1","disease_mechanism":"loss of function","disease_mechanism_id":"273"}
{"medgen_id":"C0002986","public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","alternate_symbols":[],"keywords":[],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000591289\"}]}"],"id":"1790","gard_id":"6400","alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","name":"Fabry disease","disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A."}
